All In Biotech

Drug Trial Radar · NCT06465953

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

A Phase 3, Multicenter, Open Label, Randomized, Non-comparative Two-arm Study of Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Adult Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an Isocitrate Dehydrogenase-1 (IDH1) Mutation (PyramIDH Study)

Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Dec 3, 2024

Primary completion

Nov 1, 2027

Study completion Dec 1, 2028

Sponsor

Lead sponsor
Institut de Recherches Internationales ServierAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Servier Bio-Innovation LLC
First posted
Jun 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will enroll participants with myelodysplastic syndromes (MDS) with an Isocitrate dehydrogenase protein, 1 (IDH1) mutation, who have not received treatment with a hypomethylating agent previously. Participants will be randomized to receive either ivosidenib (IVO) alone or azacitidine (AZA) alone. IVO will be administered daily throughout the 28-day treatment cycle and AZA will be administered for the first 7 days of each 28-day cycle. Study visits will be conducted every week during Cycle 1 (Days 1, 8, 15, and 22), and Day 1 of each cycle thereafter. After the last dose of treatment, participants will attend an safety follow-up visit and participants will be followed to assess overall survival. Study visits may include a bone marrow aspirate, physical exam, echocardiogram (ECHO), electrocardiogram (ECG), blood and urine analysis, and questionnaires.

Conditions

  • Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS)
  • Myelodysplastic Syndromes (MDS)

Interventions

  • IvosidenibDrug

    Two 250 mg tablets, totaling 500 mg, administered orally once daily until disease relapse or progression, unacceptable toxicity, confirmed pregnancy, undergoing HSCT, death, withdrawal of consent, lost to follow-up, or Sponsor ending the study, whichever occurs first.

  • AzacitidineDrug

    Azacitidine 75mg/m\^2/day administered by subcutaneous (SC) or intravenous (IV) injection for 1 week (7 days) of each 4-week (28 day) treatment cycle until disease relapse or progression, unacceptable toxicity, confirmed pregnancy, undergoing HSCT, death, withdrawal of consent, lost to follow-up, or Sponsor ending the study, whichever occurs first.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants achieving CR and PR by 4 monthsTime frame: Through 4 months after starting treatment

Locations

62 sites in 10 countries. Site status is shown where the registry gives one.

  • Presbyterian / St. Luke'S Medical Center

    Denver, Colorado · Recruiting

  • University of Chicago, Duchossois Center for Advanced Medicine (DCAM)

    Chicago, Illinois · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • MSKCC

    New York, New York · Recruiting

  • Unc Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina · Recruiting

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

  • Oncology Associates of Oregon

    Eugene, Oregon · Recruiting

  • University of Texas UT Southwestern Comprehensive Cancer Center

    Dallas, Texas · Recruiting

  • MD Anderson Cancer Centre

    Houston, Texas · Recruiting

  • Royal Adelaide Hospital

    Adelaide, Australia · Not yet recruiting

  • Monash Health

    Clayton, Australia · Recruiting

  • Northern Health

    Epping, Australia · Recruiting

  • Liverpool Hospital

    Liverpool, Australia · Not yet recruiting

  • Sir Charles Gairdner Hospital

    Nedlands, Australia · Recruiting

  • Calvary Mater Newcastle

    Waratah, Australia · Recruiting

  • Liga Paranaense de Combate ao Câncer - Hospital Erasto Gaertner

    Curitiba, Brazil · Recruiting

  • Centro de Pesquisa Clínica - Hospital Nove de Julho

    São Paulo, Brazil · Recruiting

  • Real E Benemérita Associação Portuguesa de São Paulo

    São Paulo, Brazil · Recruiting

  • Hospital das Clínicas da Faculdade de Medicina da USP

    São Paulo, Brazil · Recruiting

  • Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein

    São Paulo, Brazil · Recruiting

  • Casa de Saúde Santa Marcelina

    São Paulo, Brazil · Recruiting

  • Centro de Pesquisas Clínicas da Fundação Doutor Amaral Carvalho

    São Paulo, Brazil · Recruiting

  • Instituto Nacional do Câncer

    São Paulo, Brazil · Not yet recruiting

  • Chu Nantes-Hotel Dieu

    Nantes, France · Recruiting

  • Chu de Nice - Hôpital L'Archet 1

    Nice, France · Recruiting

  • Hopital Saint Louis

    Paris, France · Recruiting

  • Chu Bordeaux, Hopital Du Haut Leveque

    Pessac, France · Recruiting

  • Institut Universitaire Du Cancer Toulouse-Oncopole

    Toulouse, France · Recruiting

  • Chu Brabois

    Vandœuvre-lès-Nancy, France · Recruiting

  • Universitatsklinikum Dresden Carl Gustav Carus

    Dresden, Germany · Recruiting

  • Marien Hospital Duesseldorf

    Düsseldorf, Germany · Recruiting

  • Universitaetsmedizin Goettingen (Umg)

    Göttingen, Germany · Recruiting

  • Universitaetsklinikum Leipzig

    Leipzig, Germany · Recruiting

  • Tum Klinikum Rechts Der Isar

    Munich, Germany · Recruiting

  • Azienda Ospedaliero Universitaria Delle Marche

    Ancona, Italy · Recruiting

  • Istituto Di Ematologia "Lorenzo E Ariosto Seragnoli" - Policlinico Di S. Orsola

    Bologna, Italy · Recruiting

  • Azienda Ospedaliero-Universitaria Careggi

    Florence, Italy · Recruiting

  • Humanitas Research Hospital (Istituto Clinico Humanitas)

    Milan, Italy · Recruiting

  • Fondazione I.R.C.C.S. Policlinico San Matteo

    Pavia, Italy · Recruiting

  • Dipartimento Di Biomedicina E Prevenzione - Universita Degli Studi Di Roma "Tor Vergata"

    Roma, Italy · Recruiting

Showing 40 of 62 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.